Gastrointestinal Neoplasms
Cystadenocarcinoma, Mucinous
Cystadenoma, Mucinous
Pancreatic Cyst
Neoplasms, Cystic, Mucinous, and Serous
Cystadenoma, Serous
Cystadenoma
Pancreatic Neoplasms
Gastrointestinal Stromal Tumors
Proto-Oncogene Proteins c-kit
Piperazines
Receptor, Platelet-Derived Growth Factor alpha
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. (1/1704)
The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P<0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P<0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted. (+info)Predicting delayed anxiety and depression in patients with gastrointestinal cancer. (2/1704)
The aim of this study was to examine the possibility of predicting anxiety and depression 6 months after a cancer diagnosis on the basis of measures of anxiety, depression, coping and subjective distress associated with the diagnosis and to explore the possibility of identifying individual patients with high levels of delayed anxiety and depression associated with the diagnosis. A consecutive series of 159 patients with gastrointestinal cancer were interviewed in connection with the diagnosis, 3 months (non-cured patients only) and 6 months later. The interviews utilized structured questionnaires assessing anxiety and depression [Hospital Anxiety and Depression (HAD) scale], coping [Mental Adjustment to Cancer (MAC) scale] and subjective distress [Impact of Event (IES) scale]. Patient anxiety and depression close to the diagnosis were found to explain approximately 35% of the variance in anxiety and depression that was found 6 months later. The addition of coping and subjective distress measures did little to improve that prediction. A model using (standardized) cut-off scores of moderate to high anxiety, depression (HAD) and intrusive thoughts (IES subscale) close to the diagnosis to identify patients at risk for delayed anxiety and depression achieved a sensitivity of 75% and a specificity of 98%. Levels of anxiety and depression at diagnosis predicted a similar status 6 months later. The results also indicated that the HAD scale in combination with the IES intrusion subscale may be used as a tool for detecting patients at risk of delayed anxiety and depression. (+info)Management and outcome of patients undergoing surgery after acute upper gastrointestinal haemorrhage. Steering Group for the National Audit of Acute Upper Gastrointestinal Haemorrhage. (3/1704)
Most patients with acute upper gastrointestinal haemorrhage are managed conservatively or with endoscopic intervention but some ultimately require surgery to arrest the haemorrhage. We have conducted a population-based multicentre prospective observational study of management and outcomes. This paper concerns the subgroup of 307 patients who had an operation because of continued or recurrent haemorrhage or high risk of further bleeding. The principal diagnostic group was those with peptic ulcer. Of 2071 patients with peptic ulcer presenting with acute haemorrhage, 251 (12%) had an operative intervention with a mortality of 24%. In the non-operative group mortality was 10%. The operative intervention rate increased with risk score, ranging from 0% in the lowest risk categories to 38% in the highest. Much of the discrepancy between operative and non-operative mortality was explainable by case mix; however, for high-risk cases mortality was significantly higher in the operated group. In 78% of patients who underwent an operation for bleeding peptic ulcer there had been no previous attempt at endoscopic haemostasis. For patients admitted to surgical units, the operative intervention rate was about four times higher than for those admitted under medical teams. In patients with acute upper gastrointestinal haemorrhage operative intervention is infrequent and largely confined to the highest-risk patients. The continuing high mortality in surgically treated patients is therefore to be expected. The reasons for the low use of endoscopic treatment before surgery are not revealed by this study, but wider use of such treatments might further reduce the operative intervention rate. Physicians and surgeons have not yet reached consensus on who needs surgery and when. (+info)Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. (4/1704)
The c-kit gene encodes a transmembrane receptor kinase (KIT) which is expressed in the majority of human gastrointestinal stromal tumors (GISTs), a subtype of gastrointestinal mesenchymal neoplasms. A previous study identified mutations in the juxtamembrane (JM) domain of c-kit in five of six GISTs (Science 279: 577, 1998). To better define the frequency and spectrum of c-kit gene mutations in mesenchymal neoplasms of the GI tract that had been characterized for KIT protein expression, we examined archived tissue samples for mutations in the JM domain by PCR amplification and DNA sequencing. c-kit JM domain mutations were found in nine of 56 mesenchymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusively in GISTs (21%). Seven of the nine mutations consisted of intragenic deletions of one to 19 codons. There was one insertion mutation that added 12 codons and one missense mutation (Val560Asp). None of the mutations disrupted the downstream reading frame of the gene. The single missense mutation (Val560Asp) is very similar to the only other missense mutation reported in GISTs (Val599Asp). Of the 46 GISTs, 43 were strongly positive for KIT protein expression and negative for diffuse expression of desmin. Neither KIT expression nor gene mutations were found in gastrointestinal leiomyomas or leiomyosarcomas. We conclude that mutation of the c-kit JM domain does not occur in gastrointestinal mesenchymal neoplasms with well developed-smooth muscle differentiation, and is restricted to GISTs. However, since these mutations are only found in a minority of GISTs, further investigation into the mechanisms of c-kit gene activation in this group of neoplasms is warranted. (+info)Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. (5/1704)
An3 1 KAL I MutL homologue 1 (MLH1) is a member of the family of proteins required for DNA mismatch repair. Germ-line mutations in MLH1 lead to the cancer susceptibility syndrome hereditary nonpolyposis colorectal cancer (HNPCC). We generated mice carrying a null mutation in the Mlh1 gene. We showed that mice heterozygous and homozygous for the Mlh1 gene are predisposed to developing tumors of the gastrointestinal (GI) tract, lymphomas, and a number of other tumor types. We also examined the role of adenomatous polyposis coli gene (Apc) gene mutations in the GI tumors of Mlh1 mutant mice by different methods and showed that the GI tumors in Mlh1 mice express little or no adenomatous polyposis coli protein. When an Apc gene mutation was bred into the Mlh1 mutant mice, the GI tumor incidence increased 40-100-fold. The wild-type Apc allele in these tumors was found to contain mutations. Together, these results show that we have developed two mouse models for human HNPCC and that the mechanisms of tumor development in the GI tract of these mice involve loss of Apc gene function in a manner very similar to that seen in the GI tumors of HNPCC. (+info)Review article: current status of gastrointestinal carcinoids. (6/1704)
Carcinoid tumours are enigmatic, slow growing malignancies which occur most frequently (74%) in the gastrointestinal tract. In recent years, it has become apparent that the term 'carcinoid' represents a wide spectrum of different neoplasms originating from a variety of different neuroendocrine cell types. Carcinoid lesions are usually identified histologically by their affinity for silver salts, by general neuroendocrine markers, or more specifically by immunocytochemistry using antibodies against their specific cellular products. Within the gut, the most frequent sites are the small bowel (29%), the appendix (19%) and rectum (13%). Clinical manifestations are often vague or absent. Nevertheless, in approximately 10% of patients the tumours secrete bioactive mediators which may engender various elements of characteristic carcinoid syndrome. In many instances the neoplasms are detected incidentally at the time of surgery for other gastrointestinal disorders. The tendency for metastatic spread correlates with tumour size, and is substantially higher in lesions larger than 2.0 cm. An association with noncarcinoid neoplasms is ascribed in 8-17% of lesions. Treatment consists of radical surgical excision of the tumour, although gastric (type I and II) and rectal carcinoids may be managed with local excision. Overall 5-year survival is excellent for carcinoids of the appendix (86%) and rectum (72%), whereas small intestinal (55%), gastric (49%) and colonic carcinoids (42%) exhibit a far worse prognosis. (+info)Treatment of upper abdominal malignancies with organ cluster procedures. (7/1704)
Upper abdominal exenteration for upper abdominal malignancies was carried out in 15 patients with removal of the liver, spleen, pancreas, duodendum, all or part of the stomach, proximal jejunum and ascending and transverse colon. Organ replacement was with the liver, pancreas and duodenum plus, in some cases, a short segment of jejunum. Eleven of the 15 patients survived for more than 4 months; 2 died, after 61/2 and 10 months, of recurrent tumor. Of the 9 patients who are surviving after 61/2 to 14 months, recurrent tumor is suspected in only 1 and proven in none. Four patients with sarcomas and carcinoid tumors (2 each) have had no recurrences. The other 5 survivors had duct cell cancers (3 examples), a cholangiocarcinoma (1 example), and a hepatoma (1 example). The experience so far supports further cautious trials with this drastic cancer operation. (+info)Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. (8/1704)
OBJECTIVE: To conduct a meta-analysis of 11 randomized controlled trials comparing enteral nutritional support supplemented with key nutrients versus standard enteral nutritional support to determine effects on morbidity and mortality rates and hospital stay. BACKGROUND DATA: Recent studies have shown that malnutrition occurs in up to 30% of patients undergoing gastrointestinal surgery, resulting in an increased risk of postoperative complications and death. With the realization that key nutrients can modulate inflammatory, metabolic, and immune processes, enteral nutritional regimens (supplemented with large amounts of key nutrients) have been developed for clinical use. METHODS: Eleven prospective, randomized controlled trials evaluating 1009 patients treated with combinations of key nutrients (Impact, Immun-Aid) were evaluated. Outcome measures examined were the incidences of pneumonia, infectious complications, and death, and length of hospital stay. Meta-analyses were undertaken to obtain the odds ratio and 95% confidence interval for incidences of infectious complications, pneumonia, and death, and the weighted mean difference and 95% confidence interval for length of hospital stay. RESULTS: The provision of nutritional support supplemented with key nutrients to patients with critical illness resulted in a decrease in infectious complications when compared with patients receiving standard nutritional support and a significant reduction in overall hospital stay. Similar results were documented in patients with gastrointestinal cancer. However, there were no differences between patient groups for either pneumonia or death. CONCLUSIONS: This meta-analysis has demonstrated that nutritional support supplemented with key nutrients results in a significant reduction in the risk of developing infectious complications and reduces the overall hospital stay in patients with critical illness and in patients with gastrointestinal cancer. However, there is no effect on death. These data have important implications for the management of such patients. (+info)Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.
Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.
Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.
GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.
There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.
Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.
These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.
Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.
Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.
Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.
While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.
A pancreatic cyst is a fluid-filled sac that forms in the pancreas, a gland located behind the stomach that produces enzymes to help with digestion and hormones to regulate blood sugar levels. Pancreatic cysts can be classified into several types, including congenital (present at birth), retention (formed due to blockage of pancreatic ducts), and pseudocysts (formed as a result of injury or inflammation).
While some pancreatic cysts may not cause any symptoms, others can lead to abdominal pain, bloating, nausea, vomiting, or jaundice. Some cysts may also have the potential to become cancerous over time. Therefore, it is essential to monitor and evaluate pancreatic cysts through imaging tests such as ultrasound, CT scan, or MRI, and in some cases, endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) may be necessary for further evaluation.
Treatment options for pancreatic cysts depend on the type, size, location, and symptoms of the cyst, as well as the patient's overall health condition. Some cysts may require surgical removal, while others can be managed with regular monitoring and follow-up care. It is essential to consult a healthcare provider for proper evaluation and management of pancreatic cysts.
Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.
Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.
Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.
Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.
In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.
A serous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the serous glands, which are glands that produce a watery, lubricating fluid. This type of tumor typically develops in the ovary or the pancreas.
Serous cystadenomas of the ovary are usually filled with a clear, watery fluid and have multiple loculations (compartments). They can vary in size from a few millimeters to several centimeters in diameter. Although these tumors are benign, they can cause symptoms if they become large enough to press on surrounding organs or if they rupture and release their contents into the abdominal cavity.
Serous cystadenomas of the pancreas are less common than ovarian serous cystadenomas. They typically occur in the tail of the pancreas and can range in size from a few millimeters to several centimeters in diameter. These tumors are usually asymptomatic, but they can cause symptoms such as abdominal pain or discomfort if they become large enough to press on surrounding organs.
It is important to note that while serous cystadenomas are generally benign, there is a small risk that they may undergo malignant transformation and develop into a type of cancer known as a serous cystadenocarcinoma. For this reason, it is important for patients with these tumors to be followed closely by a healthcare provider and to have regular imaging studies and/or surgical excision to monitor for any changes in the tumor.
Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.
There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.
Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.
Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.
Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.
There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.
Gastrointestinal Stromal Tumors (GISTs) are rare, but potentially aggressive neoplasms that arise from the interstitial cells of Cajal or their precursors in the gastrointestinal tract. These tumors can be found anywhere along the digestive tract, including the stomach, small intestine, colon, and rectum. They are usually characterized by the presence of specific genetic mutations, most commonly involving the KIT (CD117) or PDGFRA genes. GISTs can vary in size and may present with a range of symptoms, such as abdominal pain, bleeding, or obstruction, depending on their location and size. Treatment typically involves surgical resection, and in some cases, targeted therapy with kinase inhibitors.
Proto-oncogene proteins c-kit, also known as CD117 or stem cell factor receptor, are transmembrane receptor tyrosine kinases that play crucial roles in various biological processes, including cell survival, proliferation, differentiation, and migration. They are encoded by the c-KIT gene located on human chromosome 4q12.
These proteins consist of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The binding of their ligand, stem cell factor (SCF), leads to receptor dimerization, autophosphorylation, and activation of several downstream signaling pathways such as PI3K/AKT, MAPK/ERK, and JAK/STAT.
Abnormal activation or mutation of c-kit proto-oncogene proteins has been implicated in the development and progression of various malignancies, including gastrointestinal stromal tumors (GISTs), acute myeloid leukemia (AML), mast cell diseases, and melanoma. Targeted therapies against c-kit, such as imatinib mesylate (Gleevec), have shown promising results in the treatment of these malignancies.
Benzamides are a class of organic compounds that consist of a benzene ring (a aromatic hydrocarbon) attached to an amide functional group. The amide group can be bound to various substituents, leading to a variety of benzamide derivatives with different biological activities.
In a medical context, some benzamides have been developed as drugs for the treatment of various conditions. For example, danzol (a benzamide derivative) is used as a hormonal therapy for endometriosis and breast cancer. Additionally, other benzamides such as sulpiride and amisulpride are used as antipsychotic medications for the treatment of schizophrenia and related disorders.
It's important to note that while some benzamides have therapeutic uses, others may be toxic or have adverse effects, so they should only be used under the supervision of a medical professional.
Piperazines are a class of heterocyclic organic compounds that contain a seven-membered ring with two nitrogen atoms at positions 1 and 4. They have the molecular formula N-NRR' where R and R' can be alkyl or aryl groups. Piperazines have a wide range of uses in pharmaceuticals, agrochemicals, and as building blocks in organic synthesis.
In a medical context, piperazines are used in the manufacture of various drugs, including some antipsychotics, antidepressants, antihistamines, and anti-worm medications. For example, the antipsychotic drug trifluoperazine and the antidepressant drug nefazodone both contain a piperazine ring in their chemical structure.
However, it's important to note that some piperazines are also used as recreational drugs due to their stimulant and euphoric effects. These include compounds such as BZP (benzylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), which have been linked to serious health risks, including addiction, seizures, and death. Therefore, the use of these substances should be avoided.
The platelet-derived growth factor receptor alpha (PDGFR-α) is a type of cell surface receptor that binds to specific proteins called platelet-derived growth factors (PDGFs). PDGFR-α is a transmembrane tyrosine kinase receptor, which means it has an intracellular portion containing tyrosine kinase enzymatic activity.
When PDGFs bind to PDGFR-α, they induce receptor dimerization and activation of the tyrosine kinase domain, leading to autophosphorylation of specific tyrosine residues on the receptor. This triggers a signaling cascade that promotes cell growth, proliferation, survival, and migration. PDGFR-α is primarily expressed in cells of mesenchymal origin, such as fibroblasts, smooth muscle cells, and glial cells.
PDGFR-α plays crucial roles during embryonic development, wound healing, and tissue repair. However, aberrant activation or mutations in PDGFR-α have been implicated in various pathological conditions, including cancer, atherosclerosis, and fibrotic disorders. Therefore, PDGFR-α is an important target for therapeutic interventions in these diseases.
Pyrimidines are heterocyclic aromatic organic compounds similar to benzene and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-member ring. They are one of the two types of nucleobases found in nucleic acids, the other being purines. The pyrimidine bases include cytosine (C) and thymine (T) in DNA, and uracil (U) in RNA, which pair with guanine (G) and adenine (A), respectively, through hydrogen bonding to form the double helix structure of nucleic acids. Pyrimidines are also found in many other biomolecules and have various roles in cellular metabolism and genetic regulation.
Pancreatic mucinous cystic neoplasm
Intraductal papillary mucinous neoplasm
Endoscopic submucosal dissection
Anaerobic infection
Neoplasm
Indolent T cell lymphoproliferative disorder of the gastrointestinal tract
Digestive system neoplasm
Anthramycin
Gastrointestinal stromal tumor
MLH1
Neuroendocrine tumor
Pancreatic serous cystadenoma
Muir-Torre syndrome
Human feces
Retroperitoneal space
Siamese cat
Toxicodynamics
Hamartoma
MedDRA
Attenuated familial adenomatous polyposis
David B. Adams
Tyrosine kinase
Carney's triad
Platelet-derived growth factor receptor A
MALT lymphoma
Neurofibromin 1
Large intestine
Simpson-Golabi-Behmel syndrome
List of MeSH codes (C04)
Targeted therapy of lung cancer
List of ICD-9 codes 140-239: neoplasms
Blastic plasmacytoid dendritic cell neoplasm
Pediatric Gastrointestinal Neoplasms: Background, Esophageal Neoplasms, Gastric Neoplasms
Pediatric Gastrointestinal Neoplasms: Overview, Esophageal Neoplasms, Gastric Neoplasms
Results of search for 'su:{Gastrointestinal neoplasms}' › WHO HQ Library catalog
Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms<...
Diagnostic approach to neuroendocrine neoplasms of the gastrointestinal tract and pancreas
Intestinal Cancer | Small Intestine Cancer | MedlinePlus
Pancreatic mucinous cystic neoplasm - Wikipedia
Pancreatic neoplasm: a unique size and presentation - Pourmorteza - Translational Gastrointestinal Cancer
Puumala Virus Infections Associated with Cardiovascular Causes of Death - Volume 19, Number 1-January 2013 - Emerging...
Diagnosis and treatment status of perioperative anemia in patients with gastrointestinal neoplasms: a multi-center study in...
Management of Malignant Alimentary Tract Obstruction
Inferior Vena Cava Filters: Products, Design Features, Indications
Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease
DAB2IP with tumor-inhibiting activities exhibits frameshift mutations in gastrointestinal cancers
NIOSHTIC-2 Search Results - Full View
Pathological Anatomy (LZ-H) 2023/2024 - University of Bologna
Liver and Other Neoplasms - Treatment Approaches - Medical Clinical Policy Bulletins | Aetna
Dr. Khalil Abuamr, MD - Gastroenterology Specialist in Topeka, KS | Healthgrades
Oncologists Near Me in Rochester, NY - Sharecare
Advanced Search Results - Public Health Image Library(PHIL)
National Ambulatory Medical Care Survey, 1997
Colorectal Cancer Screening: Client Reminders | The Community Guide
Hematology Specialists Near Me in osceola, WI - Sharecare
Epidemiology and outcome of individuals with intraductal papillary neoplasms of the bile duct
Primary signet ring cell carcinoma of the appendix: A rare case report
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements ...
Composite intestinal adenoma-microcarcinoid clues to diagnosing an under-recognised mimic of invasive adenocarcinoma | Journal...
Gastrointestinal Stromal Tumors (GISTs): Practice Essentials, Background, Pathophysiology
Prevalence and Clinical Expression of Germ Line Predisposition to Myeloid Neoplasms in Adults With Marrow Hypocellularity
Tumors12
- What Are Gastrointestinal Stromal Tumors? (medlineplus.gov)
- What Causes Gastrointestinal Stromal Tumors? (medlineplus.gov)
- Gastrointestinal stromal tumors (GISTs) account for less than 1% of GI tumors, but they are the most common mesenchymal neoplasms of the GI tract. (medscape.com)
- Background: Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors that may mimic ovarian tumor on presurgical testing. (scirp.org)
- Considering that only few patients with gastrointestinal stromal tumors have been reported in the obstetrical and gynecological literature, the awareness of such an entity by the obstetricians-gynecologists is necessary in order to facilitate coordinated approach with the general surgeons and oncologists for the optimal care of the patients. (scirp.org)
- GISTs (Gastrointestinal stromal tumors) are most common mesenchymal neoplasms of gastrointestinal tract. (scirp.org)
- 1% of all Gastrointestinal (GI) tumors and its incidence is approximately 10 - 20 per million people per year. (scirp.org)
- Gastrointestinal stromal tumors (GISTs) belong to the sarcoma group and are characterized by oncogenic mutations in the c-KIT, PDGFRA, BRAF and NF-1 genes that drive tumor growth. (clinicaltrials.gov)
- Gastric schwannoma represent only 0.2% of all gastric tumors and 4% of all benign gastric neoplasms. (sages.org)
- Gastric schwannomas are often misdiagnosed as malignant gastrointestinal stromal tumors (GIST) following EGD, EUS and PET/CT (Positron emission tomographic/computed tomographic) imaging. (sages.org)
- Neuroendocrine neoplasms comprise an ever greater ratio of primary gastrointestinal tract tumors, thanks to the improving diagn. (nel.edu)
- Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a rare, heterogeneous group of tumors that originate from the endocrine system of the gastrointestinal tract and pancreas. (karger.com)
Papillary mucinous neoplasm2
Stromal5
- Shown here is a gastric gastrointestinal stromal tumor (GIST). (medscape.com)
- Case Report: We reported a case of 55-year-old post menopausal woman who presented to us as ovarian mass which turned out to be malignant epithelioid gastrointestinal stromal tumor intraoperatively and by immunohistochemistry. (scirp.org)
- Our case was also presented as ovarian mass which turned out to be malignant epithelioid gastrointestinal stromal tumor intraoperatively and by immunohistochemistry. (scirp.org)
- Histologically the tumor showed the mass to be a malignant epitheioid gastrointestinal stromal tumor with mitoses in 8 - 9 of 10 high-power fields ( Figure 1 ). (scirp.org)
- Ayvakit is already approved for advanced SM, SM with associated hematological neoplasms, aggressive SM, mast cell leukemia and unresectable or metastatic gastrointestinal stromal tumor. (biospace.com)
Pancreas4
- GPC3 is currently used as an immunohistochemical marker for HCC, but its expression in epithelial neoplasms of the gastrointestinal (GI) tract and pancreas, a common source of liver metastasis, has not been studied in detail. (elsevierpure.com)
- In this study, we examined GPC3 immunoreactivity in 98 neoplasms of the GI tract including 30 adenocarcinomas (ADCA), 29 squamous cell carcinomas (esophageal and anal), and 39 neuroendocrine carcinomas, and 60 neoplasms of the pancreas including 22 ADCA, 26 pancreatic neuroendocrine neoplasms, and 12 pancreatic acinar cell carcinomas. (elsevierpure.com)
- Pancreatic mucinous cystic neoplasm (MCN) is a type of cystic lesion that occurs in the pancreas. (wikipedia.org)
- Most cystic lesions of the pancreas are inflammatory pseudocysts, but approximately 10% are cystic neoplasms. (medscape.com)
Mesenchymal neoplasms1
- Gastrointestinal schwannomas are rare benign neoplasms that are distinctively unique when compared to soft-tissue and central nervous system mesenchymal neoplasms. (sages.org)
Neuroendocrine neoplasms2
- Although most (7/12, 58.5%) acinar cell carcinomas were GPC3 positive, pancreatic ADCA and neuroendocrine neoplasms were GPC3 negative. (elsevierpure.com)
- The gastroenteropancreatic (GEP) system is the site of origin of about two thirds of all neuroendocrine neoplasms (NENs) of the human body. (hunimed.eu)
Cancers2
- Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. (wikigenes.org)
- ptic ulcer disease, GI motility disorders, pancreatic disease, cancers, and benign neoplasms throughout the gastrointestinal and biliary tract. (salary.com)
Biliary2
- We report a case of mucin-secreting biliary neoplasm of the ampulla of Vater diagnosed peroperatively because of unsuccessful endoscopy due to pyloric stenosis, and successfully treated with transduodenal local excision. (ispub.com)
- The Epic Biliary Endoscopic Stent System is indicated for the palliation of malignant neoplasms in the biliary tree. (bostonscientific.com)
Intraductal1
- Wu RS, Liao WJ, Ma JS, Wang JK, Wu LQ, Hou P. Epidemiology and outcome of individuals with intraductal papillary neoplasms of the bile duct. (wjgnet.com)
Patients with gastrointestinal3
- Diagnosis and treatment status of perioperative anemia in patients with gastrointestinal neoplasms: a multi-center study in Hubei Province]. (bvsalud.org)
- To investigate the incidence and treatment of perioperative anemia in patients with gastrointestinal neoplasms in Hubei Province. (bvsalud.org)
- The clinicopathological data of 7 474 patients with gastrointestinal neoplasms in 62 hospitals in 15 cities ( state ) of Hubei Province in 2019 were collected in the form of network database. (bvsalud.org)
Malignant neoplasms2
- Consequently, this article focuses on the more common benign and malignant neoplasms of the GI tract in children, in addition to information gleaned from the relatively sparse literature. (medscape.com)
- Designed to offer the ultimate combination of delivery system access and stent construction to expand options available for patient treatment and management of colonic strictures caused by malignant neoplasms. (bostonscientific.com)
Liver3
- This Clinical Policy Bulletin addresses treatment approaches for liver and other neoplasms. (aetna.com)
- Percutaneous ethanol injection (PEI) for liver neoplasms when criteria above are not met. (aetna.com)
- Consultations for gastrointestinal tract, liver, and pancreatic biopsy and research specimens. (weillcornell.org)
Gastric1
- Cancer in the body and tail may cause splenic vein obstruction, resulting in splenomegaly, gastric and esophageal varices, and gastrointestinal hemorrhage. (msdmanuals.com)
Diagnosis1
- Accurate pre-operative diagnosis of gastrointestinal schwannomas is often difficult due to the rarity of this condition. (sages.org)
Carcinoma3
- In conclusion, 14% of GI tract and pancreatic carcinomas/neoplasms (particularly pancreatic acinar cell carcinoma) can express GPC3 by immunohistochemistry. (elsevierpure.com)
- Extrapulmonary small-cell carcinoma (SCC) is a rare neoplasm that shares certain features with its pulmonary counterpart and occurs predominantly in the gastrointestinal tract (GIT). (mdpi.com)
- Colorectal carcinoma , the commonest malignant tumour of the gastrointestinal tract , is rather uncommon in Nigeria , occurring often at a relatively early age. (bvsalud.org)
Pancreatic cystic1
- [ 2 ] We report a case of enterogenous cyst of probable foregut origin that appeared clinically as a pancreatic cystic neoplasm. (medscape.com)
Cystic2
- Amongst individuals undergoing surgical resection of a pancreatic cyst, about 23 percent were mucinous cystic neoplasms. (wikipedia.org)
- Where possible, surgical resection of mucinous cystic neoplasms is preferable. (wikipedia.org)
Endoscopy2
- Gastrointestinal Endoscopy. (wikipedia.org)
- Upper gastrointestinal endoscopy failed to examine the second part of the duodenum and the ampulla of Vater due to pyloric stenosis. (ispub.com)
Medical Oncology1
- 6 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. (aacrjournals.org)
Tract cancer1
- Combined modality therapy of gastrointestinal tract cancer / P. Schlag, P. Hohenberger, U. Metzger (eds. (who.int)
Colorectal2
- Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. (wikigenes.org)
- Nonpolypoid (flat and depressed) colorectal neoplasms. (wikigenes.org)
Gastroenteropancreatic2
Resection1
- The patient underwent surgery and local resection of ampullary neoplasm was performed. (ispub.com)
Upper Gastrointestinal2
Disorders1
- Gastrointestinal Complications: Monitor for complications such as bleeding, ulceration and perforations, particularly in patients with underlying gastrointestinal disorders. (nih.gov)
Disease2
Conclusion1
- In conclusion, the high specificity of this marker for gastrointestinal neoplasms may be very interesting in follow-up studies. (pfeiffertheface.com)
Retroperitoneal1
- Histopathology report showed the retroperitoneal mass to be a malignant epithelioid gastrointestinal tumor. (scirp.org)
Lymphoma1
- A study was made of 117 patients who presented with gastrointestinal lymphoma. (nih.gov)
Stomach1
- Rarely, schwannomas can present in the gastrointestinal tract with the stomach as the most commonly affected organ. (sages.org)
Secondary1
- Skeletal survey for secondary neoplasms, etc. (albertadoctors.org)
Cytology1
- Diagnosing hematolymphoid neoplasm by evaluating fine-needle aspiration (FNA) cytology sample is controversial and requires experience and clinical skills. (cytojournal.com)
Surgery6
- Department of Gastrointestinal and Anorectal Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China. (bvsalud.org)
- Department of Gastrointestinal and Anorectal Surgery, Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, Huangshi 435000, China. (bvsalud.org)
- Department of Gastrointestinal Surgery, Xiaogan Hospital of Wuhan University of Science and Technology, Xiaogan 432600, China. (bvsalud.org)
- Department of Gastrointestinal Surgery â ¡ Ward, Xianning Central Hospital, Hubei University of Science and Technology, Xianning 437100, China. (bvsalud.org)
- The outcome after surgery is excellent as these neoplasms are generally benign in nature. (sages.org)
- post-gastrointestinal bypass surgery (e.g. (globalrph.com)